Amplia Therapeutics (ASX: ATX; OTCQB: INNMF) has announced data from the ongoing ACCENT clinical trial of narmafotinib combined with chemotherapy in advanced pancreatic cancer showing a median overall survival (OS) of 11.1 months, and five complete responses recorded to date.
According to Amplia, narmafotinib continues to be well tolerated by patients with the adverse effect profile of the narmafotinib-chemotherapy combination similar to chemotherapy alone.
The company has been selected to present its trial data, along with additional ACCENT data, at the annual meeting of the American Association of Cancer Research (AACR) meeting to be held April 17-22 in San Diego, California.
In a statement, Dr. Chris Burns, CEO and managing director of Amplia, commented, “These latest data from the ACCENT trial clearly demonstrate the significant clinical benefit of narmafotinib. The unprecedented 7.8% rate of CR’s in the first line setting provides new hope for patients with this very aggressive cancer and provides further strong support for the benefit that narmafotinib can bring when combined with other treatment modalities. We look forward to presenting a detailed analysis of the ACCENT trial at the forthcoming AACR conference.”
